SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Wenbin Li, Tian Qiu, Wenxue Zhi, Susheng Shi, Shuangmei Zou, Yun Ling, Ling Shan, Jianming Ying, Ning Lu, Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages, BMC Cancer, 2015, 15, 1

    CrossRef

  2. 2
    Janindra Warusavitarne, Justin Stebbing, Omar Faiz, Genetic variants and response to cancer treatments, Cancer, 2015, 121, 11
  3. 3
    Christos S Karapetis, Dipen Maru, Paul Waring, Jeanne Tie, Michael Z Michael, Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer, Expert Review of Molecular Diagnostics, 2015, 1

    CrossRef

  4. 4
    Michael J Duffy, Personalized treatment for patients with colorectal cancer: role of biomarkers, Biomarkers in Medicine, 2015, 9, 4, 337

    CrossRef

  5. 5
    Jacopo Martellucci, Giovanni Alemanno, Francesca Castiglione, Carlo Bergamini, Andrea Valeri, Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer, Updates in Surgery, 2015, 67, 1, 47

    CrossRef

  6. 6
    Angela N. Bartley, Stanley R. Hamilton, Select Biomarkers for Tumors of the Gastrointestinal Tract: Present and Future, Archives of Pathology & Laboratory Medicine, 2015, 139, 4, 457

    CrossRef

  7. 7
    Gemma Bruera, Katia Cannita, Alessandra Tessitore, Antonio Russo, Edoardo Alesse, Corrado Ficorella, Enrico Ricevuto, The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?, Critical Reviews in Oncology/Hematology, 2015, 93, 3, 190

    CrossRef

  8. 8
    Lei Cheng, Wei Ren, Li Xie, Ming Li, Jiang Liu, Jing Hu, Bao-Rui Liu, Xiao-Ping Qian, Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories, Cancer Chemotherapy and Pharmacology, 2014, 74, 1, 1

    CrossRef

  9. 9
    Nele Boeckx, Ken Op de Beeck, Vanessa Deschoolmeester, Guy Van Camp, Patrick Pauwels, Marc Peeters, Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives, Current Colorectal Cancer Reports, 2014, 10, 4, 380

    CrossRef

  10. 10
    Tze-Kiong Er, Chih-Chieh Chen, Luis Bujanda, Marta Herreros-Villanueva, Clinical relevance of KRAS mutations in codon 13: Where are we?, Cancer Letters, 2014, 343, 1, 1

    CrossRef

  11. 11
    Kristen K Ciombor, Richard M Goldberg, Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer, Hepatic Oncology, 2014, 1, 3, 331

    CrossRef

  12. 12
    Andrea L. Russo, Darrell R. Borger, Jackie Szymonifka, David P. Ryan, Jennifer Y. Wo, Lawrence S. Blaszkowsky, Eunice L. Kwak, Jill N. Allen, Raymond C. Wadlow, Andrew X. Zhu, Janet E. Murphy, Jason E. Faris, Dora Dias-Santagata, Kevin M. Haigis, Leif W. Ellisen, Anthony J. Iafrate, Theodore S. Hong, Mutational analysis and clinical correlation of metastatic colorectal cancer, Cancer, 2014, 120, 10
  13. 13
    Ana Sebio, Sebastian Stintzing, Stefan Stremitzer, Wu Zhang, Heinz-Josef Lenz, Panitumumab: leading to better overall survival in metastatic colorectal cancer?, Expert Opinion on Biological Therapy, 2014, 14, 4, 535

    CrossRef

  14. 14
    Ken CN Chang, Matthew J Marton, Past, current and future approaches to querying MAPK pathway activation: status and clinical implications, Personalized Medicine, 2014, 11, 8, 745

    CrossRef

  15. 15
    Shalini Sree Kumar, Timothy J Price, Amanda R Townsend, Christopher Hocking, Jennifer E Hardingham, Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies, Colorectal Cancer, 2014, 3, 2, 223

    CrossRef

  16. 16
    Gemma Bruera, Katia Cannita, Daniela Di Giacomo, Aude Lamy, Thierry Frébourg, Jean Christophe Sabourin, Mario Tosi, Edoardo Alesse, Corrado Ficorella, Enrico Ricevuto, Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx), BMC Medicine, 2013, 11, 1, 59

    CrossRef